

PRESS RELEASE

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio

Berlin, Germany – February 4, 2025

ProBioGen has launched its new, redesigned [website](#) to provide biotech and biopharma professionals with clear access to its expanded services and proprietary technologies. The platform delivers an intuitive, user-focused experience and faster access to essential information.

The new website enables visitors to efficiently and more easily explore ProBioGen's comprehensive portfolio, which includes cell line development, cell banking, process and full analytical development, GMP manufacturing, and advanced solutions for proteins, viral vectors, and vaccines. It also spotlights proprietary technologies, such as [GlymaxX®](#) and [DirectedLuck®](#), developed to enhance efficacy, boost productivity or accelerate time to clinic.

Key Benefits of the New Website:

- **Streamlined navigation:** Dedicated sections for CDMO services, technologies, news & resources, and company information makes it faster and easier than ever to find relevant content.
- **Comprehensive insights:** Detailed descriptions of ProBioGen's portfolio, alongside scientific studies, white papers, or industry updates, provide visitors with the information they need to make informed decisions and advance their projects.
- **Enhanced user experience:** A fully responsive, interactive design ensures seamless access across all devices, providing convenience to users wherever they are.

"Our relaunched website reflects ProBioGen's commitment to innovation and partnership putting our customers first," said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen. "By focusing on clarity and ease of use, the platform empowers visitors to make faster decisions, plan projects more effectively, and drive innovation in next-generation therapies."

Explore the new website at www.probiogen.de.

About ProBioGen

[ProBioGen](#) is a Berlin-based biotech company, so called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.

It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, a widely recognized hospital as one [of the best](#) in the world. 30 years later, 300 employees work at ProBioGen's three locations in Berlin.

Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

For more information about ProBioGen, follow us on [LinkedIn](#).

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer
cdmo@probiogen.de

ProBioGen Press Contact:

Sarah Wandrey
Senior Communications Manager
press@probiogen.de